31.90
-1.30 (-3.92%)
| Penutupan Terdahulu | 33.20 |
| Buka | 33.07 |
| Jumlah Dagangan | 1,568,268 |
| Purata Dagangan (3B) | 1,641,781 |
| Modal Pasaran | 3,044,600,064 |
| Harga / Jualan (P/S) | 38.52 |
| Harga / Buku (P/B) | 10.20 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -130,369.45% |
| EPS Cair (TTM) | -3.35 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.82% |
| Nisbah Semasa (MRQ) | 19.49 |
| Aliran Tunai Operasi (OCF TTM) | -279.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -171.41 M |
| Pulangan Atas Aset (ROA TTM) | -32.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Viridian Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.13 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 114.61% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vr Adviser, Llc | 30 Sep 2025 | 3,882,709 |
| Fairmount Funds Management Llc | 30 Sep 2025 | 3,459,913 |
| Maverick Capital Ltd | 30 Sep 2025 | 2,212,701 |
| Eversept Partners, Lp | 30 Sep 2025 | 1,924,306 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (UBS, 56.74%) | Beli |
| Median | 43.50 (36.36%) | |
| Rendah | 29.00 (Wells Fargo, -9.09%) | Pegang |
| Purata | 42.17 (32.19%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 31.34 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Needham | 04 Feb 2026 | 42.00 (31.66%) | Beli | 33.53 |
| 23 Dec 2025 | 42.00 (31.66%) | Beli | 32.11 | |
| Wells Fargo | 03 Feb 2026 | 29.00 (-9.09%) | Pegang | 33.53 |
| Truist Securities | 08 Jan 2026 | 40.00 (25.39%) | Beli | 30.33 |
| 24 Nov 2025 | 41.00 (28.53%) | Beli | 32.03 | |
| UBS | 07 Jan 2026 | 50.00 (56.74%) | Beli | 30.57 |
| Wedbush | 10 Dec 2025 | 47.00 (47.34%) | Beli | 32.60 |
| RBC Capital | 06 Nov 2025 | 45.00 (41.07%) | Beli | 27.50 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2026 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Pengumuman | Viridian Therapeutics Prepares for Transformational 2026 |
| 22 Dec 2025 | Pengumuman | Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease |
| 05 Dec 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Nov 2025 | Pengumuman | Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 05 Nov 2025 | Pengumuman | Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |